The European Central Bank meets on Thursday and one topic will dominate: what to do about rising sovereign bond yields which if left unchecked could derail efforts to get a coronavirus-hit economy back on track. Policymakers from president Christine Lagarde to chief economist Philip Lane have expressed unease. What will the ECB do to contain rising bond yields?
The trial of former Minneapolis police officer Derek Chauvin for the death of George Floyd was due to begin on Monday with the screening of jurors to weigh murder and manslaughter charges in a case seen as a referendum on police violence against Black Americans. The judge has set aside three weeks for jury selection alone, mindful of the difficulties finding impartial Minneapolitans in a case that has convulsed a nation and in which an image of the victim — a selfie of Floyd faintly smiling — has fast become an international icon of racial justice. The court mailed prospective jurors an unusually detailed 16-page questionnaire last year asking them what they know about Floyd's death on May 25 on the street after his arrest outside a Minneapolis grocery store.
A selection for the position of CEO and Member of the Management Board of UAB “Ignitis”, a subsidiary of AB “Ignitis grupė”, has been announced AB “Ignitis grupė” (hereinafter – the Company) informs that on 8 March 2021 it has announced the selection for the position of new CEO and Member of the Management Board of its subsidiary UAB “Ignitis” (hereinafter – Ignitis). Among the requirements set for the candidates to the Ignitis CEO and Chair of the Management Board position there are requirements of at least 5-year experience in a managerial role in the position of business development and/or product development and/or trading and/or sales; an ability to develop a technologically advanced environment suitable for innovations. You can find all requirements set for candidates in the official advertisement (link). The Company will announce the new Ignitis CEO and Member of the Management Board as a notice via the securities exchange. The current Ignitis CEO and Chair of the Management Board Darius Montvila is leaving the position due to health-related reasons. He will remain in the current position until the new CEO and Chair of the Management Board is appointed and, afterwards, will remain an advisor to the Ignitis company’s Management Board. The newly selected CEO of Ignitis would be appointed for the term of five years. They would serve as the Member of the Management Board until the current end of term of Ignitis Management Board – 31 May 2023. For more information please contact: Artūras KetleriusHead of Public Relations at Ignitis Grouparturas.ketlerius@ignitis.lt+370 620 76076
AB “Ignitis grupė” (hereinafter – the Company) informs that on 8 March 2021 it has announced the selection for the position of new CEO and Member of the Management Board of its subsidiary UAB “Ignitis” (hereinafter – Ignitis). Among the requirements set for the candidates to the Ignitis CEO and Chair of the Management Board position there are requirements of at least 5-year experience in a managerial role in the position of business development and/or product development and/or trading and/or sales; an ability to develop a technologically advanced environment suitable for innovations. You can find all requirements set for candidates in the official advertisement (link). The Company will announce the new Ignitis CEO and Member of the Management Board as a notice via the securities exchange. The current Ignitis CEO and Chair of the Management Board Darius Montvila is leaving the position due to health-related reasons. He will remain in the current position until the new CEO and Chair of the Management Board is appointed and, afterwards, will remain an advisor to the Ignitis company’s Management Board. The newly selected CEO of Ignitis would be appointed for the term of five years. They would serve as the Member of the Management Board until the current end of term of Ignitis Management Board – 31 May 2023. For more information please contact: Artūras KetleriusHead of Public Relations at Ignitis Grouparturas.ketlerius@ignitis.lt+370 620 76076
FREYR AS, (the "Company" or "FREYR"), a Norway-based developer of clean, next-generation battery cell production capacity announced today that the company's Chief Executive Officer, Tom Einar Jensen, will meet with investors at the following upcoming conference events:
Win serious brownie points this year with these clever – and useful – ideas
PRESS RELEASE NEW INDEPENDENT PUBLICATION IN THE INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES CONFIRMS THE ROLE OF MASITINIB AS A POTENTIAL THERAPY IN NEURODEGENERATIVE DISORDERS INCLUDING ALZHEIMER'S DISEASE Paris, 08 March 2021, 8am CET AB Science SA (NYSE Euronext - FR0010557264 - AB) today announced the publication of a peer-reviewed article in which the authors state that blocking hemichannels on mast cells with masitinib represents a promising novel strategy for slowing the progression of neurodegenerative diseases such as Alzheimer’s disease and amyotrophic lateral sclerosis (ALS). Hemichannels allow cell communication with the extracellular environment and have diverse physiological and pathophysiological roles in the nervous system. Entitled ‘Mast Cell and Astrocyte Hemichannels and Their Role in Alzheimer’s Disease, ALS, and Harmful Stress Conditions’, this publication [1] is freely accessible online from the International Journal of Molecular Sciences website https://doi.org/10.3390/ijms22041924. This review article [1] examines hemichannels and their contribution to mast cell degranulation in Alzheimer’s disease. Of particular interest are data from the authors in vitro and in vivo (APPswe/PS1dE9 mouse model of Alzheimer’s disease) experiments that show increased mast cell hemichannel activity after treatment with amyloid peptide (Ab25–35), with subsequent degranulation response and enhanced histamine release [2]. The number of mast cells in hippocampal and cortical areas increased drastically even before amyloid plaque deposits became evident, suggesting that mast cells are one of the first brain cells to recognize and respond to amyloid peptides, and thus may play a critical role in the onset and progression of Alzheimer’s disease. Treatment with masitinib was shown to totally prevent the amyloid-induced hemichannel-dependent mast cell activity in bone marrow-derived mast cells and brain mast cells. The authors concluded that hemichannel expressed by mast cells might serve as a molecular target with which to develop therapeutic treatments that could delay the onset and progression of Alzheimer’s disease. This research supports results from the phase 2B/3 study, AB09004, that evaluated oral masitinib in patients with mild and moderate Alzheimer’s disease. Philip Scheltens, Professor of Neurology at the Alzheimer Center Amsterdam, said: “This research provides further supportive evidence that masitinib, through its dual targeting of mast cells and microglia, has a unique and effective profile for neurodegenerative diseases such as Alzheimer's disease and amyotrophic lateral sclerosis.” As a reminder [3], AB Science recently announced topline results from its Phase 2B/3 study (AB09004) evaluating oral masitinib in patients with mild and moderate Alzheimer’s disease met its predefined primary endpoint. Study AB09004 was an international, randomized, placebo-controlled, phase 2B/3 study evaluating different doses of masitinib as a treatment of patients with confirmed mild to moderate Alzheimer’s disease. This study compared the efficacy and safety of masitinib relative to placebo after 24 weeks of treatment when administered as an add-on therapy to cholinesterase inhibitor (donepezil, rivastigmine or galantamine) and/or memantine. Two doses of masitinib were tested, masitinib 4.5 mg/kg/day and a titrated dose of masitinib from 4.5 to 6.0 mg/kg/day, with each dose having an independent control arm. The study demonstrated that masitinib 4.5 mg/kg/day (n=182) generated a significant treatment effect compared with the control arm (n=176) on the primary endpoint of change from baseline in the Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog), an instrument that measures the effect on cognition and memory (p=0.0003). The study also demonstrated that masitinib 4.5 mg/kg/day generated a significant change from baseline in Alzheimer’s Disease Cooperative Study Activities of Daily Living (ADCS-ADL) score, an instrument that assesses self-care and activities of daily living (p= 0.0381). There were significantly fewer patients reaching severe dementia stage (MMSE<10) with masitinib 4.5 mg/kg/day compared with placebo after 24 weeks of treatment (p-value= 0.0446). [1] Harcha PA, Garcés P, Arredondo C, Fernández G, Sáez JC, van Zundert B. Mast Cell and Astrocyte Hemichannels and Their Role in Alzheimer’s Disease, ALS, and Harmful Stress Conditions. International Journal of Molecular Sciences. 2021; 22(4):1924. https://doi.org/10.3390/ijms22041924 [2] Harcha PA, Vargas A, Yi C, Koulakoff AA, Giaume C, Sáez JC. Hemichannels Are Required for Amyloid β-Peptide-Induced Degranulation and Are Activated in Brain Mast Cells of APPswe/PS1dE9 Mice. J Neurosci. 2015;35(25):9526-9538. Doi:10.1523/JNEUROSCI.3686-14.2015 [3] AB Science press release. Dec 18,2020. https://www.ab-science.com/results-from-phase-2b-3-study-evaluating-masitinib-in-alzheimers-disease/ About the International Journal of Molecular SciencesThe International Journal of Molecular Sciences is an international, peer-reviewed, open access journal covering research in biochemistry, molecular and cell biology, molecular biophysics, molecular medicine, and all aspects of molecular research in chemistry. It is published by MDPI and was established in 2000. About masitinibMasitinib is a new orally administered tyrosine kinase inhibitor that targets mast cells and macrophages, important cells for immunity, through inhibiting a limited number of kinases. Based on its unique mechanism of action, masitinib can be developed in a large number of conditions in oncology, in inflammatory diseases, and in certain diseases of the central nervous system. In oncology due to its immunotherapy effect, masitinib can have an effect on survival, alone or in combination with chemotherapy. Through its activity on mast cells and microglia and consequently the inhibition of the activation of the inflammatory process, masitinib can have an effect on the symptoms associated with some inflammatory and central nervous system diseases and the degeneration of these diseases. About AB ScienceFounded in 2001, AB Science is a pharmaceutical company specializing in the research, development and commercialization of protein kinase inhibitors (PKIs), a class of targeted proteins whose action are key in signaling pathways within cells. Our programs target only diseases with high unmet medical needs, often lethal with short term survival or rare or refractory to previous line of treatment. AB Science has developed a proprietary portfolio of molecules and the Company’s lead compound, masitinib, has already been registered for veterinary medicine and is developed in human medicine in oncology, neurological diseases, and inflammatory diseases. The company is headquartered in Paris, France, and listed on Euronext Paris (ticker: AB). Further information is available on AB Science’s website: www.ab-science.com. Forward-looking Statements - AB ScienceThis press release contains forward-looking statements. These statements are not historical facts. These statements include projections and estimates as well as the assumptions on which they are based, statements based on projects, objectives, intentions and expectations regarding financial results, events, operations, future services, product development and their potential or future performance. These forward-looking statements can often be identified by the words "expect", "anticipate", "believe", "intend", "estimate" or "plan" as well as other similar terms. While AB Science believes these forward-looking statements are reasonable, investors are cautioned that these forward-looking statements are subject to numerous risks and uncertainties that are difficult to predict and generally beyond the control of AB Science and which may imply that results and actual events significantly differ from those expressed, induced or anticipated in the forward-looking information and statements. These risks and uncertainties include the uncertainties related to product development of the Company which may not be successful or to the marketing authorizations granted by competent authorities or, more generally, any factors that may affect marketing capacity of the products developed by AB Science, as well as those developed or identified in the public documents filed by AB Science with the Autorité des Marchés Financiers (AMF), including those listed in the Chapter 4 "Risk Factors" of AB Science reference document filed with the AMF on November 22, 2016, under the number R. 16-078. AB Science disclaims any obligation or undertaking to update the forward-looking information and statements, subject to the applicable regulations, in particular articles 223-1 et seq. of the AMF General Regulations. For additional information, please contact: AB ScienceFinancial Communication & Media Relations investors@ab-science.com Media Relations – USA RooneyPartnersJeffrey Freedmanjfreedman@rooneyco.com +1 646 432 0191 Media Relations – France NewCapArthur Rouilléarouille@newcap.fr +33 (0)1 44 71 00 15 Attachment Masitinib Neurology Eng VF
Japanese shares reversed course to end lower on Monday as some investors adjusted positions ahead of the end of the fiscal year, while concerns over rising U.S. bond yields also weighed on sentiment. The Nikkei share average fell 0.42% to close at 28,743.25, while the broader Topix edged down 0.14% to 1,893.58. "Investors are trying to take advantage of the recent rally to adjust their positions toward the end of the fiscal year in March," said Takashi Hiroki, chief strategist, Monex Securities.
I want to buy a house with my boyfriend – should I sell my flat?. I’m wondering if I should keep it and rent it out – and how much stamp duty we’ll pay
Storm clouds gather over roof leak insurance claim. The insurer’s get-out clauses don’t hold water as it demands proof of the Storm Christoph effect
The state that has tried to stop Black people from voting is shifting in a liberal direction to become a symbol of the new south After Black Lives Matter protests, the Richmond mayor Levar Stoney ordered the removal of Confederate statues on Monument Avenue. Photograph: Ryan M Kelly/AFP/Getty Images Having lived in Virginia most of his life, Larry Sabato can remember racially segregated schools and systematic efforts to stop Black people voting. Now 68, he observes a state that has diversified, embraced liberal values and shifted from symbol of the old south to symbol of the new. “I have to admit, as a young man I would never have believed it was possible for Virginia to move in such a strong progressive direction,” said Sabato, director of the Center for Politics at the University of Virginia. “I worked for candidates back then who were progressive. I used to joke, ‘If I work for you, you’re going to lose, you have to understand that’. And they always did. “Virginia has taught the country and the world that America can change, and sometimes can change rapidly, and in a very progressive direction.” Two dramatic examples came last month when the state general assembly voted to abolish the death penalty – an extraordinary reversal for a state that has executed more people than any other – and to make Virginia the first southern state to legalise marijuana for adult recreational use. These followed a flurry of measures that put the commonwealth, as it is known, in the vanguard on racial, social and economic issues in the American south. Last year it passed some of the strictest gun laws, loosest abortion restrictions and strongest protections for LGBTQ+ people in the region, as well as its highest minimum wage. People watch as the Stonewall Jackson statue is removed from Monument Avenue in Richmond, Virginia, on 1 July 1. Photograph: Ryan M Kelly/AFP/Getty Images Joe Biden beat Donald Trump by 10 points in Virginia in 2020. Its two US senators are Democrats, its governor is a Democrat and last year Democrats took full control of the general assembly for the first time in a quarter of a century. Such a monopoly would once have been unthinkable. Sabato reflected: “It was almost a one-party Republican state. It was Barack Obama in 2008 that finally got hundreds of thousands of young people registered and voting Larry Sabato “Virginia had been edging a little bit closer to the Democratic party because of population growth in northern Virginia and Hampton Roads and even the Richmond area. But it was Barack Obama in 2008 that finally got hundreds of thousands of, not just minorities, but also young people registered and voting and we haven’t gone back since. “The Republican party has drifted further to the right. Instead of responding to the changes and bouncing back to the middle, they’ve decided to double down. They’ve lost every single election in this state from 2010 onwards.” Sabato was speaking from his office in Charlottesville, looking out on a statue of Thomas Jefferson, the third president who, like the first, George Washington, was a Virginian. Both founding fathers owned enslaved people on sprawling estates – Monticello and Mount Vernon – that have gone far in recent years to confront that legacy for tourists, historians and children. Virginia’s long and painful history would later include Confederate generals Robert E Lee and Thomas “Stonewall” Jackson fighting to preserve slavery and destroy the union. The state capital, Richmond, was the capital of the Confederacy. The south lost the civil war but Virginia remained a bastion of Jim Crow laws that maintained racial apartheid. By the 1990s, however, Virginia had elected the first African American governor in the US and political realignment was being fuelled by growing suburbs. The expansion of Washington spilled into northern Virginia, where voters are more likely to be immigrants, college educated and liberal. Other cities have expanded and diversified. The mayors of Richmond and Charlottesville are African American. Gun control reform advocates protest outside the National Rifle Association headquarters in Fairfax, Virginia, on 14 August. Photograph: Michael Reynolds/EPA Few changes are as totemic as the demise of capital punishment. Virginia had executed nearly 1,400 people since colonial days, according to the Death Penalty Information Center. Since 1976, when the US supreme court reinstated the death penalty, it had carried out 113 executions, second only to Texas. But in voting to abolish it last month, Virginia’s general assembly noted that it is applied disproportionately to people of colour, the poor and the mentally ill. The march of progressive values is neither uniform nor irreversible. Virginia’s reforms have provoked resentment in rural areas. Tens of thousands of gun rights activists descended on Richmond last year to protest. A white supremacist rally in Charlottesville in 2017 was a stark reminder of the potential for backlash. Four years later, the statue of Lee at the centre of the protest still stands. Despite last summer’s Black Lives Matter protests, a giant Lee monument in Richmond also remains intact. Juli Briskman, a district supervisor in Loudon county, northern Virginia, said: “You don’t have to drive very far to start seeing Trump flags and Confederate flags, and often you see them together. We still have the ‘Don’t tread on me’ licence plate. I’m trying to figure out how we can take that out of the system. So Virginia still has a little ways to go but I think as a ‘southern state’ it is really leading the way right now. I’m thankful that Virginians stuck with me Ralph Northam “We’re the first state to pass the Voting Rights Act in the south and that is sitting on the governor’s desk right now. We’ve made a lot of strides in abortion access: last year the general assembly repealed a law that would have required women to get an ultrasound and have certain types of counselling before getting abortion care. We’ve passed a number of gun sense laws in ’20 and ’21, so we’re making our way.” ‘He faced the storm’ Perhaps no one personifies the often uncomfortable, but seemingly inexorable, transformation of Virginia more than Ralph Northam, the 61-year-old governor. Two years ago the Democrat was engulfed in scandal over a blackface image in his 1984 medical school yearbook. In one disastrous press conference, he seemed ready to accept a reporter’s challenge to perform Michael Jackson’s “moonwalk” dance until his wife interjected that these were “inappropriate circumstances”. Northam faced demands to resign but with his potential successor facing sexual assault allegations, managed to survive. He vowed to focus on racial equality and confronting his own white privilege. He has enthusiastically signed many of the progressive bills passed by the general assembly. Briskman, a Democrat who shot to fame by giving Trump’s motorcade the middle finger while cycling near his golf course, was among those who called for Northam to quit but now believes he has redeemed himself. “If he had resigned, we might not have gotten as much done,” she said. “It goes a long way toward reconciliation when somebody like Governor Northam can say he faced the storm and decided that he was going to turn it around and do something about it.” Protestors rally against Governor Ralph Northam outside of the governors mansion in downtown Richmond on 4 February. Photograph: Logan Cyrus/AFP/Getty Images In an interview with the Guardian on Friday, Northam acknowledged the blackface incident had been a watershed moment. “That was a difficult time for Virginia and I’m thankful that Virginians stuck with me,” he said. “We had worked on a lot of equity issues prior to February 2019 but it really allowed me to travel around: I had listening tours and meetings and I learned so much from various people across Virginia. “The more I know, the more I can do, so we’ve really been able to put a stronger focus on equity and I made it clear to our administration, to our cabinet secretaries, that whether it be agriculture or education or health or whatever, we would address the inequities that continue to exist in our society today.” Then, in 2020, came the police killing of George Floyd in Minneapolis and a nationwide uprising against racial injustice. “That was an awakening for a lot of people that look like me that hadn’t really ever thought through it in such detail,” Northam said. “So I kind of had a head start before that tragedy but I think it was an awakening. People said this just this is not right and we need to make changes.” Northam grew up in a conservative rural area and was in sixth grade when his school became racially integrated. When he got involved in politics, around 2006-07, he recalls, Virginia was still a red state but turning purple. The “blue wave” truly began with resistance to Trump’s election in November 2016, which prompted Northam to run for governor. “It’s diversity that really makes this country and, in our case, makes Virginia who we are,” he said. “We’re becoming more diverse every day and so we need to have our lights on and our doors open and make people feel welcome. In the smaller cities and in the country, it is quite conservative John Edwin Mason “We’ve really used that theme to support our base and also to draw more people to our party and supporting common sense policies. If you compare where we are today versus back in 2016, 2017, we’re essentially a blue state now.” ‘Representation matters’ Northam will soon return to work as a doctor, since state rules prevent him seeking a second consecutive term. Among the Democrats vying to succeed him in November are Terry McAuliffe, governor from 2014 to 2018, and two African American women: Jennifer Carroll Foy and Jennifer McClellan. Victory for either would be another historic breakthrough. Carroll Foy, 39, who became a member of the Virginia house of delegates in 2017, said: “I can’t speak about what happened in the past but what I can say is I know the man today, and the Ralph Northam today will go down as one of the most progressive governors that Virginia has ever had, delivering on the promises of getting us to expand Medicaid to 500,000 Virginians and helping to reform our criminal justice system.“I passed a bill to prohibit the use of chokeholds by law enforcement officers. We have just done such incredible things. I carried legalisation of marijuana for several years and now it’s passed in Virginia and that is under Governor Northam leading the charge and taking seriously his commitment to racial reconciliation.”Carroll Foy was one of the first African American women to graduate from Virginia Military Institute and is aware what message electing a woman of colour as Northam’s successor would send. “It is absolutely imperative for us to make good on what we’ve been saying,” she said. “Representation matters and for millions of little girls it’s hard to be what you can’t see. We are yet to have a Black woman lead this nation and we’re yet to have a Black woman lead in a state in this country and, while people have applauded Black women for delivering the White House and helping us win Congress, it’s not enough to thank us.“You also have to support us when we’re ready to lead, and we are ready. Now is our time. You don’t just need bills and pledges for Black women; we need them written by Black women. And I’m excited that as the next governor, I will be able to continue on the legacy that Governor Northam has started in addressing the inequities throughout all of our systems so we can ensure that Virginia’s future is better than its past.” The Pride rainbow colors are projected over a statue of Confederate general Robert E Lee, adorned with BLM for Black Lives Matter, that still stands in Richmond. Photograph: Eze Amos/Getty Images John Edwin Mason, who moved to the state in the mid-1990s and teaches history at the University of Virginia, said: “It is a remarkable change. If you had told me that Virginia was going to legalise marijuana and outlaw the death penalty, I would have been very surprised in 1995 and probably would have told you that you had been drinking a little too much to think that that would be possible. “It was not simply a largely Republican state when it came to electoral politics, but it felt very conservative and it doesn’t quite feel that way on the whole now, although of course in the smaller cities and in the country, it is quite conservative.” Mason noted that Virginia Republicans seem to be embracing Trumpism, even after the state comprehensively rejected the president in 2020. Democrats hope other southern states will do likewise. Mason added: “I think that if you are an optimistic Democratic political operative, you’re probably saying that Virginia is the harbinger of things to come. “You would point to Georgia which just elected two Democratic senators in a very similar dynamic to the way that our two Democratic senators and Democratic governor have been elected in a state that is very split along regional lines. It is a big change and, of the states of the old confederacy, Virginia is by far the bluest.”
Laurence Debroux Photo Laurence Debroux Harold van den Broek Photo Harold van den Broek Amsterdam, 8 March, 2021 – HEINEKEN today announced that after a successful tenure as Chief Financial Officer and member of the Executive Board, Laurence Debroux and the Supervisory Board have jointly agreed that she will step down after the company’s Annual General Meeting of Shareholders (AGM) on 22 April 2021. The Supervisory Board will nominate Harold van den Broek, currently President Hygiene at RB (Reckitt Benckiser), to be appointed as member of the Executive Board and Chief Financial Officer at the company’s AGM, for a period of four years. Harold van den Broek has been with RB since 2014 where he was CFO Hygiene before assuming his current role. Harold spent over 30 years in fast moving consumer goods companies in a broad range of finance roles across business units, regions and global functions. He began his career at Unilever in 1991, living and working in Europe, across Asia and in Russia. Subject to shareholder appointment, he will join HEINEKEN on 1 June 2021 and both Laurence and Harold will work together to ensure a smooth transition. Dolf van den Brink, Chairman of the Executive Board and CEO of HEINEKEN commented: “I would like to thank Laurence for her many contributions to HEINEKEN, both as CFO and as fellow Executive Board member. Over the past six years, she has strongly contributed to HEINEKEN's success. Most recently, she played a key role in steering the company through the COVID-19 crisis and shaping EverGreen, our strategic direction for the company, exploring how to accelerate and expand our sources of growth while simplifying and right sizing our cost base. Laurence leaves HEINEKEN in a strong financial position and with the finance teams in great shape, thanks to her continuous drive to develop and nurture great talent. We wish her every success in the future. I am very happy to welcome Harold to HEINEKEN and am confident that he will be an outstanding finance and business leader for the company. Harold brings deep financial expertise and strong business acumen as the current president of a multi-billion pound business. He has led large scale business transformations, has decades of consumer goods experience and brings fresh external perspective – all of which will be an asset as we embark on our EverGreen journey, enter our next phase of growth and build on the great platform established by Laurence.” Laurence Debroux said: “It has been a great privilege and honour to serve as Executive Board Member and CFO of HEINEKEN for the past 6 years. I have deeply appreciated working with so many great colleagues from all around the world and I am proud of the strength of the finance organisation. I have very much enjoyed working with Dolf and my colleagues in the Executive Team. Over the last year, we have been shaping together the strategic direction for the company to emerge stronger from the COVID-19 crisis. I leave with full confidence that under Dolf’s leadership the company is in the best of hands to embark on its next growth chapter under a renewed strategy. This has been an intense and fulfilling period, and I see now is a natural moment to hand over and take some time to chart the next phase in my professional life. I would like to express my gratitude to the Supervisory Board for their support and trust over the past 6 years.” Jean-Marc Huët Chairman of the Heineken N.V. Supervisory Board said: “On behalf of the Supervisory Board, I want to recognise and thank Laurence for her many contributions to HEINEKEN over the past years. She has our sincere thanks and we wish her the very best. I am delighted to welcome Harold to HEINEKEN. We very much look forward to working with him and to benefiting from his proven delivery on strategy and considerable experience as a business leader.” -END-Press enquiries Sarah Backhouse / Michael Fuchs E-mail: pressoffice@heineken.com Tel: +31-20-5239-355 Investor and analyst enquiriesFederico Castillo Martinez / Janine Ackermann / Robin AchtenE-mail: investors@heineken.comTel: +31-20-5239-590 Editorial information About HEINEKENHEINEKEN is the world's most international brewer. It is the leading developer and marketer of premium beer and cider brands. Led by the Heineken® brand, the Group has a portfolio of more than 300 international, regional, local and specialty beers and ciders. HEINEKEN is committed to innovation, long-term brand investment, disciplined sales execution and focused cost management. Through "Brewing a Better World", sustainability is embedded in the business. HEINEKEN has a well-balanced geographic footprint with leadership positions in both developed and developing markets. It employs over 84,000 employees and operates breweries, malteries, cider plants and other production facilities in more than 70 countries. Heineken N.V. and Heineken Holding N.V. shares trade on the Euronext in Amsterdam. Prices for the ordinary shares may be accessed on Bloomberg under the symbols HEIA NA and HEIO NA and on Reuters under HEIN.AS and HEIO.AS. HEINEKEN has two sponsored level 1 American Depositary Receipt (ADR) programmes: Heineken N.V. (OTCQX: HEINY) and Heineken Holding N.V. (OTCQX: HKHHY). Most recent information is available on HEINEKEN's website: www.theheinekencompany.com and follow us on LinkedIn, Twitter and Instagram. Market Abuse RegulationThis press release contains inside information within the meaning of Article 7(1) of the EU Market Abuse Regulation. Attachments Press release HEINEKEN announces CFO succession (8_3_2021) Laurence Debroux Harold van den Broek
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART DIRECTLY OR INDIRECTLY, IN AUSTRALIA, CANADA, JAPAN OR THE UNITED STATES OR ANY OTHER JURISDICTION IN WHICH SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL. Commencement of application period for Private Placement in Interoil Exploration and Production ASA Interoil Exploration and Production ASA (the "Company") refers to the announcement published on 4 March 2021 in which the Company announced the signing of two transactions as well as a private placement of new shares in the Company with gross proceeds of up to the NOK equivalent of EUR 999,999 (the "Private Placement"). The Private Placement is directed towards Norwegian investors and international institutional investors pursuant to and in compliance with applicable exemptions from relevant registration, filing and prospectus requirements, and subject to other applicable selling restrictions. The minimum subscription amount in the private placement will be NOK 10,000. The subscription price in the Private Placement is established at NOK 1.33 per share. This price was calculated on the basis of a 90-day, volume-weighted average price plus a 10 percent discount, as of close of trading on 3 March 2021. The application period commences today, 8 March 2021, at 09:00 (CET) and will close on 15 March 2021 at 16:30 (CET). The Company reserves the right to close or extend the application period at any time at its sole discretion, at short notice. Applications in the Private Placement may be made by completing and returning the attached Application Agreement to retail@dnb.no. Norwegian investors with access to VPS investor services may also submit applications online using the following link: https://investor.vps.no/sc/servlet/no.vps.sc.servlets.SCLogonServlet?ISIN=XL0010024681&TSted=07910&Sig=b2742320c86ad31c54088fd2d04a833eb45441c498014eff079b37bf0f0ca1b5 Allocations of shares in the Private Placement will be made at the discretion of the Company's Board of Directors and the completion of the Private Placement is conditional upon approval by the Company's Board of Directors. Further information regarding the Private Placement and the terms thereof, is included in the attached Application Agreement. Important Notice The distribution of this announcement and other information may be restricted by law in certain jurisdictions. Copies of this announcement are not being made and may not be distributed or sent into any jurisdiction in which such distribution would be unlawful or would require registration or other measures. Persons into whose possession this announcement or such other information should come are required to inform themselves about and to observe any such restrictions. The securities referred to in this announcement have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the "Securities Act"), and accordingly may not be offered or sold in the United States absent registration or an applicable exemption from the registration requirements of the Securities Act and in accordance with applicable U.S. state securities laws. The Company does not intend to register any part of the offering or their securities in the United States or to conduct a public offering of securities in the United States. This communication is only being distributed to and is only directed at persons in the United Kingdom that are (i) investment professionals falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended (the "Order") or (ii) high net worth entities, and other persons to whom this announcement may lawfully be communicated, falling within Article 49(2)(a) to (d) of the Order (all such persons together being referred to as "relevant persons"). This communication must not be acted on or relied on by persons who are not relevant persons. Any investment or investment activity to which this communication relates is available only for relevant persons and will be engaged in only with relevant persons. Persons distributing this communication must satisfy themselves that it is lawful to do so. This announcement is for information purposes only and is not to be relied upon in substitution for the exercise of independent judgment. It is not intended as investment advice. This announcement is an advertisement and is not a prospectus for the purposes of Regulation (EU) 2017/1129 of the European Parliament and of the Council of 14 June 2017 on prospectuses to be published when securities are offered to the public or admitted to trading on a regulated market, and repealing Directive 2003/71/EC (as amended) as implemented in any Member State. This announcement has been published by Mr. Geir Arne Drangeid (Partner and Senior Advisor, First House AS) at 08:00 CET on 8 March 2021. This information is subject of the disclosure requirements of section 5-12 of the Norwegian Securities Trading Act. Attachments Why invest - Facts about the placement Application Agreement - complete form by hand Application Agreement - complete form in Word
AUGUST GETTY Atelier is pleased to announce the fashion house's newest creation, TINITUS, revealed on March 4th, 2021, during Paris Fashion Week.
Atlantic Therapeutics, the Galway-based company pioneering a non-invasive, wearable treatment for urinary incontinence, today announced it has raised significant new investment from the Borski Fund (Netherlands) and the Western Development Commission (Ireland).
LOS ANGELES, March 08, 2021 (GLOBE NEWSWIRE) -- Calibre Scientific is pleased to announce the acquisition of HUBERLAB, a premier supplier of diversified products to laboratories in Switzerland. HUBERLAB establishes an important distribution hub for Calibre Scientific, joining BIOZOL and Dianova to expand Calibre Scientific’s representation in the DACH region. HUBERLAB, headquartered in Aesch, Switzerland, is a leading supplier of equipment, consumables, and supplies to laboratories in academic, pharmaceutical, chemical, healthcare and industrial markets. Through its catalog of world-class brands, modern ecommerce experience, and technical expertise, the business has earned the trust of laboratory professionals throughout Switzerland. With the acquisition of HUBERLAB, Calibre Scientific expands its geographic reach through a highly regarded distributor in the Swiss market. “HUBERLAB is a unique addition to Calibre Scientific,” said Dr. Ben Travis, CEO of Calibre Scientific. “We’re looking forward to combining their one-stop shop catalogue with our niche offerings and expanding our customer relationships across the DACH region.” This is Calibre Scientific’s third acquisition in the region and first located in Switzerland. Marc Hatebur, CEO of HUBERLAB, said, “Joining Calibre Scientific gives us a chance to offer our customers an even broader set of products and services, while providing tremendous growth opportunities for HUBERLAB and its employees.” About Calibre Scientific Calibre Scientific is a diversified global provider of life science reagents, tools, instruments, and other consumables to the lab research, diagnostics, industrial, and biopharmaceutical communities. Calibre Scientific owns a portfolio of 17 life science and diagnostic companies, that have an unrivaled ability to address the unique challenges of their respective markets. Our global reach extends into over 100 countries, empowering customers all over the world. Headquartered in Los Angeles, California, Calibre Scientific continues to grow across a wide array of verticals and geographies, further expanding its product offering and global footprint to laboratories around the world. For more information, visit www.calibrescientific.com, or contact Brice Geoffrion, Director of Business Development, at bgeoffrion@calibrescientific.com, or +1 (310) 651-8285.
Novogene Europe, a leading provider of genomic services and solutions, has announced the launch of a Clinical Service to provide its European customers with next-generation sequencing (NGS) services and solutions for their clinical samples.
Trondheim, 8 March 2021: NORBIT today announces an agreement for acquisition of business and assets from the Norwegian IoT company StalkIT and associated companies. “Through the acquisition we are broadening our product offering and strengthening our position in the asset tracking vertical. This is a strategic fit with NORBIT’s plans to grow a new subsegment based on selected IoT/5G niche applications," says Per Jørgen Weisethaunet, CEO of NORBIT. StalkIT has developed flexible tracking services with tracking devices and software tailored to support and maintain control of assets. Currently, the business has approximately 20 000 active tracking units in use. As part of the transaction, NORBIT will in addition to the technology, the customer base and the running business also assume ownership of a Spanish legal entity with six employees covering business development, software development and customer support. The StalkIT business will be integrated in NORBIT´s business segment ITS. NORBIT has been one of the partners of StalkIT on industrialization and production of its tracking units. The transaction price is agreed to NOK 24 million and is expected to be financed by use of NORBIT´s available credit lines. Completion of the transaction is contingent on a satisfactory outcome of a due diligence and shareholder approval in StalkIT and associated companies. Closing is expected to take place during March 2021. As communicated in January, NORBIT is currently in advanced and exclusive negotiations regarding an add-on acquisition of an undisclosed European company which is operating in the asset and vehicle tracking domain, offering a substantial share of recurring subscription-based revenues. “The two acquisitions jump start our strategy of building a new vertical within our ITS segment with a subscription-based revenue model where we also take advantage of NORBIT’s existing key competence within high-volume wireless low power devices and utilizing our sales and distribution platform” says Per Jørgen Weisethaunet. For further queries, please contact: Per Jørgen Weisethaunet, CEO, +47 959 62 915Per Kristian Reppe, CFO, +47 900 33 203 About NORBIT ASANORBIT is a global provider of tailored technology to carefully selected niches. The company’s business is structured to address its key markets; Oceans is offering tailored technology solutions to global maritime markets, Intelligent Traffic Systems (ITS) is offering connectivity solutions for vehicle identification and tracking, and Product Innovation and Realization (PIR) is offering R&D services and contract manufacturing to key customers. NORBIT is headquartered in Trondheim, Norway, with manufacturing facilities in Selbu and Røros, Norway and 14 offices and subsidiaries around the world. For more information: www.norbit.com The information is such that NORBIT is required to disclose in accordance with the EU Market Abuse Regulation, and is subject to the disclosure requirements pursuant to Section 5-12 of the Norwegian Securities Trading Act. The information was submitted for publication by Chief Financial Officer, Per Kristian Reppe, at 8 March 2021 08:00 CET.
Leuven, BE, Boston, MA, US – March 8, 2021 – 08.00 AM CET – Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company developing next generation standard-of-care ophthalmic therapies, with a clinical stage portfolio in diabetic eye disease, today announces its management will participate and meet with investors at the following upcoming virtual meetings in March: · H.C. Wainwright Global Life Sciences Conference - March 9-10, 2021 Pre-Recorded Company Presentation, featuring Tom Graney, CFA, CFO to be made live on March 9 at 7:00 am EST.The presentation will be available in the events section of Oxurion’s website at www.oxurion.com.A replay will be available for approximately 90 days following the conference. ·14th Annual European Life Sciences CEO Forum - March 10-11, 2021Pre-Recorded Company Presentation, featuring Patrik De Haes, MD, CEO available on demand for all registered users to view on events portal. ·33rd Annual Roth Conference - March 15-17, 2021Oxurion to join panel discussion entitled ‘Disruptive Back of the Eye Therapies’ which will take place on March 16 at 9:00 am EST. END For further information please contact: Oxurion NVWouter Piepers, Global Head of Investor Relations& Corporate CommunicationsTel: +32 16 75 13 10 / +32 478 33 56 32wouter.piepers@oxurion.comEU Citigate Dewe Rogerson David Dible/ Sylvie Berrebi/Frazer HallTel: +44 20 7638 9571oxurion@citigatedewerogerson.com USWestwicke, an ICR CompanyChristopher BrinzeyTel: +1 617 835 9304chris.brinzey@westwicke.com About Oxurion Oxurion (Euronext Brussels: OXUR) is a biopharmaceutical company developing next generation standard of care ophthalmic therapies, which are designed to better preserve vision in patients with diabetic macular edema (DME), the leading cause of vision loss in diabetic patients worldwide. Oxurion is aiming to build the leading global franchise in the treatment of DME, based on the successful development of its two novel therapeutics: THR-149, a plasma kallikrein inhibitor being developed as a potential new standard of care for DME patients who respond sub-optimally to anti-VEGF therapy. THR-149 has shown positive topline Phase 1 results for the treatment of DME. The Company is currently conducting a Phase 2 clinical trial evaluating multiple injections of THR-149 with DME-patients who previously responded sub-optimally to anti-VEGF therapy. THR-149 was developed in conjunction with Bicycle Therapeutics PLC (NASDAQ: BCYC) THR-687 is a pan-RGD integrin inhibitor, that is initially being developed as a potential new standard of care for all DME patients. Positive topline results in a Phase 1 clinical study assessing THR-687 as a treatment for DME were announced in January 2020. THR-687 is expected to enter a Phase 2 clinical trial by mid-2021 after receiving regulatory approval. THR-687 is an optimized compound derived from a broader library of integrin inhibitors in-licensed from Galapagos NV (Euronext & NASDAQ: GLPG). Oxurion is headquartered in Leuven, Belgium, and is listed on the Euronext Brussels exchange under the symbol OXUR. More information is available at www.oxurion.com. Important information about forward-looking statements Certain statements in this press release may be considered “forward-looking”. Such forward-looking statements are based on current expectations, and, accordingly, entail and are influenced by various risks and uncertainties. The Company therefore cannot provide any assurance that such forward-looking statements will materialize and does not assume an obligation to update or revise any forward-looking statement, whether as a result of new information, future events, or any other reason. Additional information concerning risks and uncertainties affecting the business and other factors that could cause actual results to differ materially from any forward-looking statement is contained in the Company’s Annual Report. This press release does not constitute an offer or invitation for the sale or purchase of securities or assets of Oxurion in any jurisdiction. No securities of Oxurion may be offered or sold within the United States without registration under the U.S. Securities Act of 1933, as amended, or in compliance with an exemption therefrom, and in accordance with any applicable U.S. state securities laws.
Yahoo Home